<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133428</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-SAC-2018-01</org_study_id>
    <nct_id>NCT04133428</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness.</brief_title>
  <official_title>Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective study is to demonstrate if there is any difference in the
      treatment response to Sacubitril-Valsartan depending on the ventricular disfunction ethiology
      in patients with severe systolic disfunction heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">July 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the treatment response to Sacubitril-Valsartan depending on the ventricular dysfunction etiology.</measure>
    <time_frame>Up to 6 months after the beginning of the Sacubitril-Valsartan treatment</time_frame>
    <description>Verify if there is any difference in the response to the treatment with Sacubitril-Valsartan depending on the ventricular dysfunction etiology, ischemic or non-ischemic (idiopathic/familiar,toxic, volume overload,etc) excluding enolic, of patients with severe systolic heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the microRNA genetic profile in heart failure.</measure>
    <time_frame>Up to 6 months after the beginning of the Sacubitril-Valsartan treatment</time_frame>
    <description>Study of the microRNA genetic profile in heart failure as an indicator of the cardiac remodeling process and see its response and changes after undergoing Sacubitril-Valsartan treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate the connection between the biomarkers levels in heart failure and the cardiac remodeling parameters.</measure>
    <time_frame>Up to 6 months after the beginning of the Sacubitril-Valsartan treatment</time_frame>
    <description>Demonstrate if there´s a possible relation between the biomarkers levels in heart failure and an improvement in the cardiac remodeling.</description>
  </other_outcome>
  <other_outcome>
    <measure>Study the levels of auricular natriuretic peptide (ANP), auricular natriuretic peptide type B (BNP), urocortin and type I-C terminal pro-collagen.</measure>
    <time_frame>Up to 6 months after the beginning of the Sacubitril-Valsartan treatment</time_frame>
    <description>Study the levels of ANP, BNP and urocortin as cardioprotective molecules as well as type I-C terminal pro-collagen as measurement of peripheral blood fibrosis.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sacubitril-Valsartan cohort</arm_group_label>
    <description>Patients with severe systolic disfunction (left ventricle ejection fraction&lt;40%) heart failure that remain functional class II, III or IV after at least 3 months of optimal treatment and after being evaluated by the cardiologist by doing an echocardiography, blood test and clinical evaluation, start Sacubitril-Valsartan treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>Evaluation of the Sacubitril-Valsartan treatment effectiveness.
As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.
Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made.</description>
    <arm_group_label>Sacubitril-Valsartan cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 18 years old, diagnosed with heart failure and EF ≤ 40%, that after
        being treated with optimal medical treatment for at least 3 months, remain in functional
        class II, III or IV. Being this the actual indication for Sacubitril-Valsartan.

        100 consecutive patients will be included, 50 of whom with ischemic etiology of heart
        failure and 50 with non-ischemic, excluding patients with enolic etiology, any
        contraindication for the treatment intake and that have already been treated with
        Sacubitril-Valsartan.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years old.

          -  Ejection fraction (EF) ≤ 40%.

          -  Treated with optimal medical treatment for at least 3 months and remained in
             functional class II, III or IV.

          -  Patients with ischemic or non ischemic etiology.

        Exclusion Criteria:

          -  Patients with enolic etiology.

          -  Patients with any contraindication for taking Sacubitril-Valsartan.

          -  Patients with EF &gt;40%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonzalo Baron Esquivias</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gonzalo Baron Esquivias</last_name>
    <phone>955 00 80 00</phone>
    <email>gonzalo.baron.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonzalo Baron Esquivias</last_name>
      <phone>955 00 80 00</phone>
      <email>gonzalo.baron.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Severe systolic disfunction</keyword>
  <keyword>Sacubitril-Valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

